-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, O7VHWwdVCKUOsOQHIcLfeb/Ot5Iz6QAMa6vEqMKvjU19+6MiggcepAPb5L2Np/VI Yj8dpbTdHJpL6OvBg4GBgg== /in/edgar/work/0000950172-00-001241/0000950172-00-001241.txt : 20000712 0000950172-00-001241.hdr.sgml : 20000712 ACCESSION NUMBER: 0000950172-00-001241 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXTER CORP CENTRAL INDEX KEY: 0000028582 STANDARD INDUSTRIAL CLASSIFICATION: [2851 ] IRS NUMBER: 060321410 STATE OF INCORPORATION: CT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: SEC FILE NUMBER: 001-05542 FILM NUMBER: 670887 BUSINESS ADDRESS: STREET 1: ONE ELM ST CITY: WINDSOR LOCKS STATE: CT ZIP: 06096 BUSINESS PHONE: 8602927675 MAIL ADDRESS: STREET 1: ONE ELM ST CITY: WINDSOR LOCKS STATE: CT ZIP: 06096 DEFA14A 1 0001.txt SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant |X| Filed by a Party other than the Registrant |_| Check the appropriate box: |_| Preliminary Proxy Statement |_| Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |_| Definitive Proxy Statement |_| Definitive Additional Materials |X| Soliciting Material Pursuant to Rule 14a-12 - ------------------------------------------------------------------------------ (Name of Registrant as Specified In Its Charter) - ------------------------------------------------------------------------------ (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): |X| No fee required. |_| Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (a) Title of each class of securities to which transaction applies: --------------------------------------------------------------------------- (b) Aggregate number of securities to which transaction applies: - ------------------------------------------------------------------------------ (c) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11: - ------------------------------------------------------------------------------ (d) Proposed maximum aggregate value of transaction: --------------------------------------------------------------------------- (e) Total Fee paid: --------------------------------------------------------------------------- |_| Fee paid previously with preliminary materials. |_| Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid:___________________________________________ (2) Form, Schedule or Registration Statement No.:_____________________ (3) Filing Party: ____________________________________________________ (4) Date Filed: ______________________________________________________ As filed with the Commission on July 11, 2000 INFORMATION CONCERNING PARTICIPANTS (FURNISHED PURSUANT TO RULE 14A-12 OF THE SECURITIES EXCHANGE ACT OF 1934) Dexter Corporation ("Dexter"), and the following persons named below may be deemed to be "participants" in the solicitation of proxies from the shareholders of Dexter in connection with the special meeting of shareholders of Dexter for the purpose of approving the proposed merger with Invitrogen Corporation. The participants in this solicitation may include the directors of Dexter (K. Grahame Walker (Chairman and Chief Executive Officer of Dexter), Charles H. Curl, Henrietta Holsman Fore, Bernard M. Fox, Robert M. Furek, Martha Clark Goss, Edgar G. Hotard, Peter G. Kelly, Jean-Francois Saglio and George M. Whitesides) and the following executive officers of Dexter: Kathleen Burdett, Vice President and Chief Financial Officer; David G. Gordon, President and Chief Operating Officer, John D. Thompson, Senior Vice President, Strategic and Business Development; Bruce H. Beatt, Vice President, General Counsel and Secretary; Ronald C. Benham, Vice President and President-- Electronic Materials; John B. Blatz, Vice President-- Environmen tal and Process Management; John B. Lockwood, Vice President-- Taxes; Jeffrey W. McClelland, Vice President and President-- Adhesive and Coating Systems; Lawrence D. McLure, Vice President-- Human Resources; A. Duncan Middleton, Vice President and President-- Nonwoven Materials; Rosanne Potter-- Treasurer; and Dale Ribaudo, Controller. As of the date of this communication, none of the foregoing participants individually own in excess of 1 percent of Dexter's Common Stock or in the aggregate in excess of 3 percent of the Dexter's Common Stock. Additional information about the directors and executive officers of the Company is included in the Dexter's Proxy Statement for its 2000 Annual Meeting of Stockholders filed with the SEC on June 2, 2000, and will be included in a joint proxy statements/prospectuses and other relevant documents concerning the proposed transaction to be filed by Dexter, Invitrogen and Life Technologies, Inc. with the SEC. INVESTORS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ON THE PROPOSED TRANSACTION. Investors will be able to obtain the documents free of charge at the SEC's website (www.sec.gov). The proxy statement/prospectus and such other documents may also be obtained for free from Dexter Corporation by directing such request to: Dexter Corporation, One Elm Street, Windsor Locks, Connecticut 06096, Attention: Investor Relations, (860) 292-7675. -----END PRIVACY-ENHANCED MESSAGE-----